News is breaking today that Replimune Group, Inc.'s (REPL) Biologics License Application ("BLA") requesting approval for its drug candidate RP1 (vusolimogene oderparepvec) in the indication of anti-PD ...
Sign up for the Slatest to get the most insightful analysis, criticism, and advice out there, delivered to your inbox daily. Do you hear that solemn clang? People on ...
Hosted on MSN
REPL vs IOVA: FDA decision day could test biotech bulls’ conviction on these melanoma plays
・Analysts estimate about 116% upside for REPL, compared to a 124% upside for IOVA from current levels. ・Amtagvi, already approved for melanoma, helped Iovance generate about $264 million in product ...
In recent years, the idea of a “crisis of men and boys” has taken center stage in the cultural conversation. That can feel like a pendulum swing: from making space for women to examining men’s ...
Two years ago, Megan Agnew, a writer for The Sunday Times, in London, set the internet alight with her deft, disturbing profile of Hannah Neeleman, a former ballerina who moved to a Utah farm with her ...
Hosted on MSN
REPL stock on track for worst drop in nearly 7 months ahead of FDA decision on skin cancer drug
・The FDA issued a complete response letter regarding the application for RP1 in combination with Nivolumab for the treatment of advanced melanoma in late July. ・Following months of engagement between ...
Ms. Lipman is the author of “That’s What She Said: What Men and Women Need to Know About Working Together” and other books. “Believe women” was the defining message of the #MeToo movement. Today, ...
Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results